Capsigen

Capsigen is a private, pre-clinical stage biotech focused on solving the critical delivery challenges in gene therapy through advanced capsid engineering. Its core technology, the Transcription-Dependent Directed Evolution (TRADE™) platform, enables the rapid discovery and optimization of novel AAV capsids tailored to specific disease criteria, with a claimed timeline of about one year to a fit-for-purpose candidate. The company has established a strategic research collaboration with Biogen, signaling early validation of its platform for central nervous system and neuromuscular disorders, and operates as a platform technology company seeking partnerships to advance novel gene therapies.

Proprietary Transcription-Dependent Directed Evolution (TRADE™) platform that uses cell type-specific mRNA expression as a readout to engineer novel AAV capsids with enhanced potency, specificity, and translational potential.

Capsigen operates in a competitive field of AAV engineering companies, including Dyno Therapeutics (partnered with Roche, Novartis), Affinia Therapeutics, and StrideBio, among others. Large biopharma firms also have internal efforts. Differentiation is claimed through the TRADE™ platform's use of transcriptional readouts and ability to perform in vivo selection in clinically relevant models without cell sorting.